BackTonix Pharmaceuticals Holding Overview

Tonix Pharmaceuticals Holding Common Stock

Latest common stock for TNXP: $14K.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$14000.00
100.00% YoYΔ $7000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Tonix Pharmaceuticals Holding Common Stock History

Loading

Tonix Pharmaceuticals Holding vs. peers: Common Stock Comparison

Loading

Tonix Pharmaceuticals Holding Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Tonix Pharmaceuticals Holding (TNXP) FAQ

Tonix Pharmaceuticals Holding posts a common stock of $14K as of March 2026. That compares with $7K in the prior-year period — up 100.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Tonix Pharmaceuticals Holding's common stock was $7K. The latest reading is $14K — a 100.0% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Common Stock is one piece of Tonix Pharmaceuticals Holding's financial statement story. At $14K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for TNXP's common stock usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Tonix Pharmaceuticals Holding's other metric pages and overview cover the third.

Judging Tonix Pharmaceuticals Holding against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in common stock easier to interpret. Start with $14K here, then scan peer and history charts to see if the gap is persistent.